AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

BACKGROUND: There is an urgent unmet clinical need for the identification of novel therapeutics for the treatment of COVID-19. A number of COVID-19 late phase trial platforms have been developed to investigate (often repurposed) drugs both in the UK and globally (e.g. RECOVERY led by the University...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Gareth O., FitzGerald, Richard, Jaki, Thomas, Corkhill, Andrea, Reynolds, Helen, Ewings, Sean, Condie, Susannah, Tilt, Emma, Johnson, Lucy, Radford, Mike, Simpson, Catherine, Saunders, Geoffrey, Yeats, Sara, Mozgunov, Pavel, Tansley-Hancock, Olana, Martin, Karen, Downs, Nichola, Eberhart, Izabela, Martin, Jonathan W. B., Goncalves, Cristiana, Song, Anna, Fletcher, Tom, Byrne, Kelly, Lalloo, David G., Owen, Andrew, Jacobs, Michael, Walker, Lauren, Lyon, Rebecca, Woods, Christie, Gibney, Jennifer, Chiong, Justin, Chandiwana, Nomathemba, Jacob, Shevin, Lamorde, Mohammed, Orrell, Catherine, Pirmohamed, Munir, Khoo, Saye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311065/
https://www.ncbi.nlm.nih.gov/pubmed/34311777
http://dx.doi.org/10.1186/s13063-021-05458-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311065/
https://www.ncbi.nlm.nih.gov/pubmed/34311777
http://dx.doi.org/10.1186/s13063-021-05458-4

Ejemplares similares